Periodic Reporting for period 1 - SMARTER (Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologiesand advanced process control)

Autologous immunotherapies achieved impressive treatment results in patients with blood cancers. The next-generation personalised immunotherapies include tumour-infiltrating lymphocytes (TIL) to overcome the limitations of adaptive therapy in the treatment of solid tumours...